Pharmacological approach to cardiovascular risk in metabolic syndrome

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Disorders

Background:

• Metabolic syndrome is a complex condition with multifactorial pathogenesis.
• Oxidative stress is a key mechanism in the development of metabolic syndrome.
• Addressing only cardiovascular risk factors may be insufficient for preventing events in metabolic syndrome patients.

Purpose of the Study:

• To explore the role of oxidative stress in metabolic syndrome.
• To evaluate therapeutic strategies that target oxidative stress and metabolic dysregulation.
• To investigate synergistic effects of combined treatments for cardiovascular risk reduction.

Main Methods:

• Review of existing literature on metabolic syndrome pathogenesis and oxidative stress.
• Analysis of the mechanisms of action for drugs targeting the renin-angiotensin system, glucose, and lipid metabolism.
• Consideration of nutraceuticals and dietary restriction in conjunction with pharmacological interventions.

Main Results:

• Oxidative stress mediates the effects of hemodynamic and metabolic abnormalities in metabolic syndrome.
• Drugs targeting the renin-angiotensin system (ACE inhibitors, ARBs) and metabolic pathways (statins) are relevant.
• Nutraceuticals and dietary restriction show potential for synergistic effects.

Conclusions:

• Metabolic syndrome requires multifaceted treatment approaches targeting underlying mechanisms like oxidative stress.
• Combined therapies including ACE inhibitors, ARBs, statins, nutraceuticals, and dietary changes may offer synergistic benefits.
• These strategies can help prevent functional and structural changes contributing to high cardiovascular risk in metabolic syndrome.